Moving Beyond the Pillars of Cancer Treatment: Perspectives From Nanotechnology

Siamof, Cerise M.; Goel, Shreya; Cai, Weibo

doi:10.3389/fchem.2020.598100

Cited by 25 publications

(19 citation statements)

References 106 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The applications of nanotechnology have brought favorable improvements to traditional therapeutic techniques. The final clinical outcomes can be improved through certain therapies and/or combination therapies, including personalized treatment, reduced healthcare, and accessible healthcare in clinic ( Siamof et al, 2020 ; Figure 4 ).…”

Section: Nanomedicine Monotherapies For Melanomamentioning

confidence: 99%

See 1 more Smart Citation

Recent Progress in Nanomedicine for Melanoma Theranostics With Emphasis on Combination Therapy

Guan

Zhu

2021

Front. Bioeng. Biotechnol.

View full text Add to dashboard Cite

Melanoma is an aggressive type of skin cancer with increasing incidence and high mortality rates worldwide. However, there is still a lack of efficient and resolutive treatment strategies, particularly in clinical settings. Currently, nanomedicine, an emerging area in the medical field, is being widely investigated in small animal models to afford melanoma theranostics. However, several problems, such as tumor heterogeneity, and drug resistance treatment with a single therapy, remain unresolved. Previous reviews have primarily focused on monotherapy for melanoma in the context of nanomedicine. In this review article, we summarize the recent progress in the application of nanomedicine for melanoma treatment, with particular attention to combination therapy based on nanomedicine to achieve optimized therapeutic output for melanoma treatment. In addition, we also highlight the fluorescence-guided strategies for intraoperative melanoma detection, especially in the near-infrared imaging window with greatly improved imaging contrast and penetration depth.

show abstract

Section: Nanomedicine Monotherapies For Melanomamentioning

confidence: 99%

Section: Nanomedicine Monotherapies For Melanomamentioning

confidence: 99%

Recent Progress in Nanomedicine for Melanoma Theranostics With Emphasis on Combination Therapy

Guan

Zhu

2021

Front. Bioeng. Biotechnol.

View full text Add to dashboard Cite

show abstract

“…OS generally develops via cell proliferation perturbation, dysregulation of cell cycle, and mutations in DNA, and around 70% of osteosarcoma cases showed chromosomal aberrations [ 3 ]. Existing chemo-therapeutic medication does not show a significant effect in combating cancer [ 4 , 5 ]. Although there are a variety of modern treatment strategies available for treating cancer, these strategies still have limitations such as re-occurrence, metastasis, low success rate, and several side effects [ 6 , 7 ].…”

Section: Introductionmentioning

confidence: 99%

Targeting Akt/NF-κB/p53 Pathway and Apoptosis Inducing Potential of 1,2-Benzenedicarboxylic Acid, Bis (2-Methyl Propyl) Ester Isolated from Onosma bracteata Wall. against Human Osteosarcoma (MG-63) Cells

et al. 2022

View full text Add to dashboard Cite

Onosma bracteata Wall. is an important medicinal and immunity-enhancing herbs. This plant is commonly used in the preparation of traditional Ayurvedic drugs to treat numerous diseases. Inspired by the medicinal properties of this plant, the present study aimed to investigate the antiproliferative potential and the primary molecular mechanisms of the apoptotic induction against human osteosarcoma (MG-63) cells. Among all the fractions isolated from O. bracteata, ethyl acetate fraction (Obea) showed good antioxidant activity in superoxide radical scavenging assay and lipid peroxidation assay with an EC50 value of 95.12 and 80.67 µg/mL, respectively. Silica gel column chromatography of ethyl acetate (Obea) fraction of O. bracteata yielded a pure compound, which was characterized by NMR, FTIR, and HR-MS analysis and was identified as 1,2-benzene dicarboxylic acid, bis (2-methyl propyl) ester (BDCe fraction). BDCe fraction was evaluated for the antiproliferative potential against human osteosarcoma MG-63, human neuroblastoma IMR-32, and human lung carcinoma A549 cell lines by MTT assay and exhibited GI50 values of 37.53 μM, 56.05 μM, and 47.12 μM, respectively. In Mg-63 cells, the BDCe fraction increased the level of ROS and simultaneously decreased the mitochondria membrane potential (MMP) potential by arresting cells at the G0/G1 phase, suggesting the initiation of apoptosis. Western blotting analysis revealed the upregulation of p53, caspase3, and caspase9 while the expressions of p-NF-κB, p-Akt and Bcl-xl were decreased. RT-qPCR studies also showed upregulation in the expression of p53 and caspase3 and downregulation in the expression of CDK2, Bcl-2 and Cyclin E genes. Molecular docking analysis displayed the interaction between BDCe fraction with p53 (−151.13 kcal/mol) and CDK1 (−133.96 kcal/mol). The results of the present work suggest that the BDCe fraction has chemopreventive properties against osteosarcoma (MG-63) cells through the induction of cell cycle arrest and apoptosis via Akt/NF-κB/p53 pathways. This study contributes to the understanding of the utilization of BDCe fraction in osteosarcoma treatment.

show abstract

“…Radiation therapy (RT) is central to the management of an estimated 50% of cancer patients, either on its own or in combination with surgery and/or systemic treatment, in both curative and non‐curative settings 1,2 . Although tumour response to RT is traditionally attributed to its direct cytoreductive effect, an increasing body of evidence suggests that crosstalk between tumour and immune cells within the tumour microenvironment (TME) can play a significant role in this process 3‐7 .…”

Section: Introductionmentioning

confidence: 99%

Irradiation immunity interactions

et al. 2022

View full text Add to dashboard Cite

The immune system can influence cancer development by both impeding and/ or facilitating tumour growth and spread. A better understanding of this complex relationship is fundamental to optimise current and future cancer therapeutic strategies. Although typically regarded as a localised and immunosuppressive anti-cancer treatment modality, radiation therapy has been associated with generating profound systemic effects beyond the intended target volume. These systemic effects are immune-driven suggesting radiation therapy can enhance anti-tumour immunosurveillance in some instances. In this review, we summarise how radiation therapy can positively and negatively affect local and systemic anti-tumour immune responses, how co-administration of immunotherapy with radiation therapy may help promote anti-tumour immunity, and how the use of immune biomarkers may help steer radiation therapy-immunotherapy personalisation to optimise clinical outcomes.

show abstract

Moving Beyond the Pillars of Cancer Treatment: Perspectives From Nanotechnology

Cited by 25 publications

References 106 publications

Recent Progress in Nanomedicine for Melanoma Theranostics With Emphasis on Combination Therapy

Recent Progress in Nanomedicine for Melanoma Theranostics With Emphasis on Combination Therapy

Targeting Akt/NF-κB/p53 Pathway and Apoptosis Inducing Potential of 1,2-Benzenedicarboxylic Acid, Bis (2-Methyl Propyl) Ester Isolated from Onosma bracteata Wall. against Human Osteosarcoma (MG-63) Cells

Irradiation immunity interactions

Contact Info

Product

Resources

About